The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03786562|
Recruitment Status : Recruiting
First Posted : December 26, 2018
Last Update Posted : March 16, 2020
|Condition or disease||Intervention/treatment||Phase|
|Abdominal Obesity||Drug: Intrathecal Morphine Drug: Intrathecal Morphine + Intravenous Nalbuphine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Intravenous Nalbuphine on Postoperative Nausea and Vomiting With Intrathecal Morphine in Abdominoplastic Surgery.|
|Actual Study Start Date :||March 8, 2019|
|Estimated Primary Completion Date :||March 2020|
|Estimated Study Completion Date :||September 2020|
|Placebo Comparator: Placebo group||
Drug: Intrathecal Morphine
|Active Comparator: Nalbuphine group||
Drug: Intrathecal Morphine + Intravenous Nalbuphine
- postoperative nausea and vomiting [ Time Frame: 24 hours ]
A verbal descriptive scale (VDS) was used to assess the severity of PONV. ( no nausea=0, severe nausea= 10)
by postoperative nausea and vomiting scale which range (o no nasuea to 10 sever vomating).
A verbal descriptive scale (VDS) was used to assess the severity of PONV .
- postoperative pain and puririts. [ Time Frame: 24 hours ]Visual analogue scale (VAS) pain scores (no pain = 0, worst possible pain = 10).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03786562
|Contact: Mohamed Bakri, Profemail@example.com|
|Assiut University Hospital||Recruiting|
|Contact: Eman Ismail, A professor|